Adil Javed

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

5-HT_2AReceptors Stimulate ACTH, Corticosterone, Oxytocin, Renin, and Prolactin Release and Activate Hypothalamic CRF and Oxytocin-Expressing Cells

Louis D. Van de Kar, Adil Javed, Yahong Zhang et al. · Journal of Neuroscience · 2001 · 207 citations · Full text

Multiple sclerosis in US minority populations

Omar Khan, Mitzi Williams, Lilyana Amezcua et al. · Neurology Clinical Practice · 2015 · 113 citations · Full text

Ethnicity, Family Medicine, Health Care Disparity +18

COVID-19 in multiple sclerosis patients and risk factors for severe infection

Farhan Chaudhry, Helena Bulka, Anirudha Rathnam et al. · Journal of the Neurological Sciences · 2020 · 81 citations · Full text

Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis

Xuan Feng, Nicholas P. Reder, Mounica Yanamandala et al. · Journal of the Neurological Sciences · 2011 · 76 citations · Full text

Autoimmune Disease, Neurological Disorder, Lupus +11